Nano Dimension Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly29.7MTarget: Withdrawn (previously $130M - $140M full-year 2026 range)
Adjusted EBITDA Loss Quarterly-12.5MTarget: Withdrawn (previously $40M - $50M full-year 2026 loss range)
Total Cash and Marketable Securities Quarterly441.6MTarget: Over $400M at closing of proposed Infinite Epigenetics transaction
Annualized Cash Burn Reduction Annually25MTarget: Targeting significant reduction via divestitures ($10M from AME/Fabrica, $15M from Markforged)
Watch Items
- Definitive Agreement and Due Diligence with Infinite EpigeneticsTrigger: Expiration of the 30-day mutual exclusivity period (around July 15, 2026)Action: Monitor SEC filings for the execution of a definitive merger agreement or termination of talks.
- Extraordinary General Meeting (EGM) of ShareholdersTrigger: Scheduled meeting date on July 31, 2026Action: Track shareholder votes on the continuation of the strategic alternatives review and proposals to replace board directors.
- Closing of Markforged Sale to StratasysTrigger: Expected closing in the second half of 2026Action: Verify receipt of $42.5 million in cash and execution of the transition services agreement.
- Activist Shareholder Opposition (Murchinson and Oramed)Trigger: Public statements and proxy solicitations opposing the Infinite Epigenetics transactionAction: Evaluate the risk of litigation, proxy contests, or blockages of the required S-4 registration and shareholder approvals.
Research as of 19 Jun 2026